Improved Outcomes with Adjuvant Abemaciclib in Early Breast Cancer

Significant Survival Benefits

Adjuvant abemaciclib, when combined with endocrine therapy (ET), has shown a statistically significant and clinically relevant improvement in overall survival (OS) compared to standard ET. This finding pertains to patients diagnosed with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−), node-positive, high-risk early breast cancer (EBC). These results were highlighted in the recently published Phase 3 monarchE trial.

Study Findings and Long-term Benefits

The monarchE trial, featured in the October 2025 issue of Annals of Oncology, demonstrated sustained benefits in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) over a 7-year period for patients receiving adjuvant abemaciclib plus ET. Abemaciclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, is approved for use in high-risk EBC as well as advanced breast cancer in both first and second-line treatment settings.

Standard of Care and Treatment Protocol

The current standard of care for patients with HR+, HER2−, node-positive, high-risk EBC is two years of adjuvant abemaciclib combined with ET. At a 54-month mark, the combination therapy showed sustained and clinically meaningful improvements in both IDFS and DRFS. Although OS is the primary measure for evaluating the efficacy and safety of cancer treatments, it is important to note that OS events in HR+ breast cancer tend to occur gradually. The monarchE trial provided primary OS results alongside updated IDFS and DRFS outcomes at a median follow-up of 6.3 years.

Study Design and Patient Cohorts

The monarchE trial is a global, randomized, open-label Phase 3 study aimed at assessing the efficacy and safety of abemaciclib combined with ET versus standard ET in adults diagnosed with HR+, HER2−, node-positive, high-risk EBC. A total of 5,637 patients were randomly assigned in a 1:1 ratio to receive either at least 5 years of ET with abemaciclib (n=2,808) or without abemaciclib (n=2,829), with treatment duration set for two years across two distinct cohorts.

The majority of participants were classified in Cohort 1 (n=5,120; 91%), which included patients with either four or more positive pathological axillary lymph nodes or one to three nodes presenting Grade 3 disease and/or tumors measuring five centimeters or larger. Cohort 2 (n=517; 9%) consisted of patients having one to three positive nodes, tumors graded below 3, tumors smaller than five centimeters, and a central Ki-67 score of 20% or above. The intent-to-treat (ITT) population encompassed all patients included in both cohorts.

Endpoints and Efficacy Results

The primary efficacy endpoint was IDFS, established in accordance with the Standardized Definitions for Efficacy End Points (STEEP) system. Significant secondary efficacy endpoints included DRFS and OS. Safety endpoints assessed treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) occurring within five years post-randomization, hospitalizations, and clinical laboratory abnormalities.

In Cohort 1, findings indicated that the addition of abemaciclib to ET led to a 15.8% reduction in the risk of death compared to standard ET (HR 0.842, 95% CI 0.722–0.981; two-sided P = 0.027). The efficacy outcomes for OS, IDFS, and DRFS in Cohort 1 were consistent with the overall ITT population. Specifically, total deaths recorded were 630, with 286 (11.2%) in the abemaciclib-ET arm versus 344 (13.4%) in the ET-only arm, indicating a 16.5% lower risk of death in those receiving abemaciclib-ET.

Long-term Survival Rates

The 7-year IDFS and DRFS rates were reported at 77.0% versus 70.1% and 79.5% versus 74.0% for the abemaciclib-ET group compared to the ET group, respectively. These results underscore the potential of adjuvant abemaciclib in enhancing outcomes for patients with high-risk early breast cancer.